A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day (QOD) and Once Weekly (QW) dosing schedules.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Patient must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy

• Has adequate organ function

• Is ECOG Performance Scale 0-1

• Has a negative urine pregnancy test if patient is female

• Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

• Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment

• Is currently participating or has participated in a study with an investigational compound or device within 28 days

• Has a primary central nervous system tumor

• Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure

• Is a known diabetic who is taking insulin or oral antidiabetic therapy

• Is pregnant or breastfeeding or planning to become pregnant during the study

• Is positive HIV antibody, HBs antigen or HCV antibody